Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 7:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Red Blood Cell Transfusions Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Blood Warming in Preterm Infants to Decrease Hypothermia

NCT05170633
View directory record Official record
Conditions
Preterm Birth, Blood Transfusion Complication, Hypothermia
Interventions
Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
Device
Lead sponsor
University of South Carolina
Other
Eligibility
24 Weeks to 32 Weeks
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Phase 2 Interventional

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

NCT00030550
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
thalidomide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Not applicable Interventional

SAHaRA: A Randomized Controlled Trial

NCT03309579
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
Liberal RBC Transfusion Strategy, Restrictive RBC Transfusion Strategy
Other
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Not applicable Interventional Results available

Red Cell Storage Duration and Outcomes in Cardiac Surgery

NCT00458783
View directory record Official record
Conditions
Blood Transfusion, Cardiac Surgery
Interventions
Prolonged RBC storage, Short RBC storage
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
3,942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 20, 2026, 7:13 PM EDT
Completed No phase listed Observational

Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients

NCT05255445
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Pediatric Cancer
Interventions
Red Blood Cell (RBC) Transfusion
Biological
Lead sponsor
Westat
Other
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Not applicable Interventional

MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions

NCT00749372
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
T2* Cardiac and Liver MRI
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Phase 2 Interventional Results available

Transfusion Strategies in Pediatric Cardiothoracic Surgery

NCT00350220
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
transfusion strategy, Low Hb transfusion group
Other
Lead sponsor
University of Rochester
Other
Eligibility
4 Months to 7 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Phase 3 Interventional Results available

Myocardial Ischemia and Transfusion

NCT02981407
View directory record Official record
Conditions
Myocardial Infarction, Anemia
Interventions
Red Blood Cell Transfusion
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
3,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
60
States / cities
Little Rock, Arkansas • Los Angeles, California • Danbury, Connecticut + 48 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Phase 2 Interventional

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

NCT01904682
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
10
States / cities
Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 20, 2026, 7:13 PM EDT
Terminated Not applicable Interventional

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

NCT02179359
View directory record Official record
Conditions
Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia, Paroxysmal Nocturnal Hemoglobinuria, Glanzmann Thrombasthenia, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Non-Malignant Hematologic Disorders
Interventions
Reduced Toxicity Ablative Regimen, Reduced Intensity Preparative Regimen, Myeloablative Preparative Regimen
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 20, 2026, 7:13 PM EDT
Recruiting Not applicable Interventional

Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

NCT06710418
View directory record Official record
Conditions
Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Myeloid Neoplasm
Interventions
Activity Tracking, Biospecimen Collection, Cognitive Assessment, Electronic Health Record Review, Packed Red Blood Cell Transfusion, Quality-of-Life Assessment
Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Phase 1 Interventional

Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer

NCT00294203
View directory record Official record
Conditions
Anemia
Interventions
Epoetin Alfa group, Placebo group
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Not applicable Interventional

Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status

NCT02835937
View directory record Official record
Conditions
Red Blood Cell Transfusions, Anemia, Hematology, Oncology, Ambulatory Care
Interventions
No-Transfuse
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

NCT01203514
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions
Erythropoietin, Sham Comparator
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Days
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
9
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Phase 1 Interventional Results available

The Effect of Blood Transfusion on Blood Flow to the Intestines of Premature Infants

NCT00167388
View directory record Official record
Conditions
Anemia of Prematurity
Interventions
feed during blood transfusion
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Weeks to 38 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Phase 3 Interventional Results available

Myocardial Ischemia and Transfusion Pilot

NCT01167582
View directory record Official record
Conditions
Myocardial Infarction, Unstable Angina, Coronary Artery Disease
Interventions
Red blood cell transfusion
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
Boston, Massachusetts • New Brunswick, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis

NCT02253654
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Anemia, Renal Dialysis, Erythrocyte Transfusion
Interventions
Epoetin alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Cerritos, California • Glendale, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 20, 2026, 7:13 PM EDT
Active, not recruiting Phase 3 Interventional Results available

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414
View directory record Official record
Conditions
Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Anemia
Interventions
ACE-536, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
14
States / cities
Los Angeles, California • Orlando, Florida • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 20, 2026, 7:13 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Los Alamitos, California • New Haven, Connecticut • St. Petersburg, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Blood Transfusion in Healthy Volunteers

NCT01226498
View directory record Official record
Conditions
Blood Transfusion, Autologous
Interventions
Red blood Cells auto-transfusion
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Phase 1 Interventional Results available

Biotin-RBC Transfusion in SCD

NCT04426591
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
Drug · Device
Lead sponsor
Marianne Yee
Other
Eligibility
2 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 20, 2026, 7:13 PM EDT
Completed No phase listed Observational

Blood Storage Related Mortality and Adverse Effects in Trauma Patients

NCT07341139
View directory record Official record
Conditions
Transfusion Adverse Reaction, Major Trauma, Blood Product Transfusion for All Conditions
Interventions
Not listed
Lead sponsor
Kocaeli City Hospital
Government
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

NCT03802916
View directory record Official record
Conditions
Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions
Deferiprone DR tablets 1000 mg (Low dosage), Deferiprone DR tablets 1000 mg (High dosage)
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 20, 2026, 7:13 PM EDT
Completed Not applicable Interventional

Restrictive Versus Liberal Transfusion Protocol in Infants Undergoing Cardiac Surgery

NCT01484886
View directory record Official record
Conditions
Impaired Oxygen Delivery, Congenital Heart Disease
Interventions
Red blood cell transfusion
Other
Lead sponsor
University of Rochester
Other
Eligibility
Up to 7 Months
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 20, 2026, 7:13 PM EDT